Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NXP 900

Next Previous
Drug Profile

NXP 900

Alternative Names: eCF-506; NXP-900

Latest Information Update: 28 Oct 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Edinburgh
  • Developer Nuvectis Pharma; University of Edinburgh
  • Class Antineoplastics; Carbamates; Piperidines; Pyrazoles; Pyrimidines; Small molecules
  • Mechanism of Action Proto-oncogene protein c-yes inhibitors; Src-family kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Non-small cell lung cancer; Solid tumours
  • No development reported Squamous cell cancer

Most Recent Events

  • 28 Oct 2026 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease) in USA (PO)
  • 17 Aug 2026 Nuvectis Pharma initiates enrolment in the phase Ib trial for Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater, Inoperable/Unresectable) in USA (PO) (NCT07784959)
  • 28 May 2026 No recent reports of development identified for preclinical development in Squamous-cell-cancer in USA (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top